Completed PHASE2 INTERVENTIONAL 1-arm NCT01741116

Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer

A Phase II Study of TKI258 in Patients With Castration-resistant Prostate Cancer

Sponsor: Korean Cancer Study Group

Conditions Hormone Refractory Prostate Cancer

Interventions TKI258

Updated 7 times since 2017 Last updated: Feb 16, 2021 Started: Nov 30, 2012 Primary completion: Dec 31, 2014 Completion: Oct 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Hormone Refractory Prostate Cancer and is currently completed. Korean Cancer Study Group leads this study, which shows 7 recorded versions since 2012 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Mar 2021 — Jul 2024 [monthly]

Completed PHASE2

Status: Unknown Status → Completed
Jan 2021 — Mar 2021 [monthly]

Unknown Status PHASE2

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

First recorded

Nov 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Korean Cancer Study Group

Data source: Korean Cancer Study Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea